Infliximab 5 mg/kg showed no clear difference in clinical remission defined as CDAI < 150 at week 6 compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
Infliximab 5 mg/kg showed no clear difference in clinical response defined by reduction of CDAI score by ≥ 100 at… compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
Azathioprine + infliximab probably leads to higher clinical remission compared with infliximab (moderate certainty).
Azathioprine + infliximab probably leads to higher clinical remission off steroids compared with infliximab (moderate certainty).
Azathioprine + infliximab probably leads to higher mucosal healing compared with infliximab (moderate certainty).
Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
Methotrexate + infliximab showed no clear difference in failure to enter remission at 14 weeks or 24 weeks (Feagan 2014) compared with infliximab alone (low certainty).
It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
Methotrexate + infliximab showed no clear difference in withdrawals due to adverse event (Feagan 2014) compared with infliximab alone (low certainty).
Methotrexate + infliximab showed no clear difference in proportion of patients maintaining remission compared with infliximab +/‐ placebo (low certainty).
It is very uncertain whether azathioprine and infliximab changes maintenance of remission compared with infliximab (very low certainty).
It is very uncertain whether azathioprine and infliximab changes adverse events compared with infliximab (very low certainty).
It is very uncertain whether azathioprine and infliximab changes withdrawals due to adverse events compared with infliximab (very low certainty).
It is very uncertain whether azathioprine and infliximab changes serious adverse events compared with infliximab (very low certainty).
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
Infliximab 5–10 mg/kg may leads to higher clinical response defined as improvement in the scores on the CDAI… compared with placebo (low certainty).